-
Uncategorized3 months agoIsomAb appoints CEO to lead development of angina treatment
Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). ...
-
Uncategorized3 months agoClot-busting drug could harm stroke treatment response
A clot-busting drug may stop promising stroke medicine from working properly, research reveals. Researchers at the University of Manchester found the clot-busting therapy, known as tissue...
-
Uncategorized3 months agoThis week in Drug Discovery (16 – 20 March)
News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been...
-
Uncategorized3 months agoEvotec to receive $10m as kidney cancer trial launches
Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3...
-
Uncategorized3 months agoLilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for...
-
Uncategorized3 months agoFDA finds lack of evidence for dry eye disease drug approval
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an...
-
Uncategorized3 months agoTGA approves trial for first-in-human multiple myeloma therapy
Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma. The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum...
-
Uncategorized3 months agoMestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors...
-
Uncategorized3 months agoFDA grants Fast Track Designation to rare disease treatment
The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for the rare paediatric disease late-infantile neuronal ceroid lipofuscinosis (LINCL/CLN2 disease). ...
-
Uncategorized3 months agoGenomics initiative could boost AI-designed therapeutics
A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics. The Trillion Gene Atlas,...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
